Rohto Pharmaceutical Co.,Ltd. (RPHCF)
ValueMarkers Composite Index
DCF data not available
Rohto Pharmaceutical Co.,Ltd. (RPHCF) — VMCI valuation read
Composite valuation read on RPHCF: VMCI 68/100 against a Consumer Defensive sector median of 50. The 18-point above-median print is the headline number for Rohto Pharmaceutical Co.,Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for RPHCF: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on RPHCF: RPHCF trades at 17.0x earnings, 6% below the Consumer Defensive median of 18.0x; ROIC of 17.0% sits 7.0pp above the Consumer Defensive median (10.0%); net debt to EBITDA of -1.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Consumer Defensive closes the value frame.
RPHCF fell 2.5% over the trailing 7 days, with a +3.8% read on a 30-day basis.
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.
Related Stocks in Consumer Defensive
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.